Keyphrases
Pharmacology
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Therapeutic Implications
100%
Type 2 Diabetic Patients
40%
Glucose-lowering Drugs
40%
Hyperglycemia
20%
Health Systems
20%
Low Risk
20%
A1 Receptor
20%
Disease Pathogenesis
20%
Glucagon-like
20%
Mechanism of Action
20%
Management Strategy
20%
Biguanides
20%
Thiazolidinediones
20%
Sulfonylurea
20%
Safety Profile
20%
Cardiovascular Safety
20%
Receptor Agonist
20%
Natural History
20%
Hypoglycemia Risk
20%
Novel Agents
20%
Treatment Options
20%
Dipeptidyl peptidase-4 (DPP-4)
20%
Long-term Safety
20%
Future Therapies
20%
Pharmacodynamics
20%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
20%
Metabolic Control
20%
Weight Control
20%
Pharmacokinetic Profile
20%
Glycaemia
20%
Global Epidemic
20%
Treatment Algorithm
20%
Long-term Prognosis
20%
Personalized Management
20%
Complementary Mechanism
20%
Pharmacokinetics-pharmacodynamics (PK-PD)
20%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Patient with Type 2 Diabetes
40%
Health Care
20%
Thiazolidinedione
20%
Hypoglycemia
20%
Hyperglycemia
20%
Cardiovascular System
20%
Biguanide Derivative
20%
Sulfonylurea
20%
Dipeptidyl Peptidase-4 Inhibitor
20%
Pharmacodynamics
20%
Glucagon-Like Peptide-1 Agonist
20%
Sodium Glucose Cotransporter 2 Inhibitor
20%
Metabolic Regulation
20%
Weight Control
20%
Pharmacokinetics
20%
Diseases
20%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Hyperglycemia
20%
Hypoglycemia
20%
Thiazolidinedione
20%
Biguanide Derivative
20%
Sulfonylurea
20%
Pharmacokinetics
20%
Dipeptidyl Peptidase IV Inhibitor
20%
Pharmacodynamics
20%
Sodium Glucose Cotransporter 2 Inhibitor
20%
Glucagon Like Peptide 1 Receptor Agonist
20%
Diseases
20%